TMates review

Compare the complete selected purchase

TMates lists compounded semaglutide and tirzepatide with injectable and oral format options. The default injectable one-month cards are $249 and $297 respectively. Medication, shipping and ongoing support are described as included. The actual chosen preparation still needs the clinician’s decision and a clear final quote. ^{[1] [2]}

This is a useful starting point for a reader comparing a bundled service. It is not evidence that the two formulations are interchangeable or that selecting a card guarantees a prescription. Keep the commercial plan and the clinical decision separate.

Compare another coordinated-care purchase in our MyStart Health review.

A lower equivalent has a larger term attached

Semaglutide cards list $650 for three months, $1,050 for six and $1,900 for twelve, with the last shown as $158 per month. Tirzepatide lists $800, $1,299 and $1,999 for those terms, with a $167 annual monthly equivalent. ^{[1] [2]}

The larger totals should travel with the smaller numbers. Public cards do not settle whether the selected amount is paid immediately or in installments, or how renewal works. A long-plan equivalent should not be compared with a flexible one-month debit until those arrangements and the actual supply are clear. ^[3]

Keep the plan total and actual debit together in the complete treatment-cost planner.

The format choice changes the evidence question

The product pages identify compounded preparations and present oral as well as injectable choices. Default injectable pricing does not establish the oral product’s formula, price or performance. A familiar ingredient name cannot make evidence for a different finished medicine apply automatically. ^{[1] [2]}

FDA distinguishes compounds from approved generic drugs and advises using compounding for a medical need that an approved drug cannot meet. The prescriber should explain the proposed preparation. A lower price or a same-price-across-doses claim does not establish clinical equivalence or a reason to change treatment independently. ^[5]

Separate finished-product evidence with the formulation evidence guide.

The refund cutoff precedes a parcel arriving

The August 2025 terms offer a full refund before medical-history review and after review when the patient does not qualify for any medication-assisted weight-loss plan. They deny refunds when an eligible patient’s prescription is written and transmitted to a pharmacy. ^[3]

The product’s cancel-anytime line should not be treated as a satisfaction guarantee after that stage. The terms also keep payment plans in place when a refund is not approved. Confirm the future cancellation deadline and any outstanding obligation before choosing a longer purchase, rather than wait until an order is already committed. ^{[1] [3]}

Compare the full commitment in our provider comparisons.

Clinical access is not insurance approval

TMates describes visits, coaching and medication in its general FAQ. Its independent treating providers remain responsible for care, and TMates says it is not a compounding facility. The actual dispensing pharmacy and follow-up arrangement should be identifiable for the selected prescription. ^{[1] [3] [4]}

The FAQ’s general insurance statement is not proof that a particular compounded preparation or service will be reimbursed. The terms explicitly decline to guarantee reimbursement and leave denied costs with the patient. Compare the actual cash obligation and available clinical contact instead of building a budget around presumed coverage. ^{[3] [4]}

For a different care-membership and bundle distinction, read our Zealthy review.

Give the continuing relationship more weight than the headline

TMates can be compared when a reader wants medication coordination and follow-up in one arrangement. Its testimonials and promotional weight-loss figures do not show that buying this service reproduces a branded drug trial or produces a predictable personal result. ^{[1] [2]}

LifeMD is a separate clinical-access option to assess for its own medicine scope, care charges and coverage support. Sprout offers another bundled structure. Choose between the actual service agreements; neither alternative should be assumed to supply the same prescription or eliminate the need for an individual clinical decision.

For the separate clinical-access comparison, see our LifeMD review.

Compare a different bundled-payment structure in our Sprout Health review.

For a separate clinical-access fee and pharmacy payment arrangement, read our GoodRx weight-care review.

Understanding the cost

Default injectable semaglutide: one month $249; three months $650; six months $1,050; twelve months $1,900 ($158/month displayed equivalent). Injectable tirzepatide: one month $297; three months $800; six months $1,299; twelve months $1,999 ($167/month equivalent). Confirm actual debit schedule, supply, renewal and any separate clinical costs. Oral option pricing is not established by the injectable default. ^{[1] [2] [3]}